Stephan Cho

3 weeks ago | hematologyadvisor.com | Stephan Cho

Extended anticoagulation using reduced-dose apixaban was found to be noninferior to using full-dose apixaban in preventing recurrent venous thromboembolism (VTE) in patients who had active cancer in a clinical trial, results of which were reported in the New England Journal of Medicine.

2 months ago | hematologyadvisor.com | Stephan Cho

Among patients with relapsed or refractory large B cell lymphoma (LBCL) who receive lisocabtagene maraleucel in the real-world setting, outcomes may be similar to those seen in pivotal trials leading to the drug’s approval, according to research published in Blood Advances. Lactate dehydrogenase levels prior to lymphodepletion appeared to be predictive of outcomes, the authors added in their report.

Feb 10, 2025 | hematologyadvisor.com | Stephan Cho

Chimeric antigen receptor (CAR) T-cell therapy idecabtagene vicleucel (ide-cel) continues to demonstrate a favorable benefit-risk profile compared with standard regimens (SRs) in triple-class-exposed (TCE) relapsed and refractory multiple myeloma (R/R MM), according to research published in Blood.

May 31, 2024 | hematologyadvisor.com | Tori Rodriguez |Stephan Cho

As survival rates and treatment options continue to increase for patients with diffuse large B-cell lymphoma (DLBCL) in the Western world, those in low- and middle-income countries (LMICs) face ongoing challenges and disparities in diagnosis, treatment access, and outcomes.

Jul 13, 2023 | clinicalpainadvisor.com | Stephan Cho